Butafosfan first showed up in veterinary circles during the twentieth century, filling a real need for a safe source of organic phosphorus. Earlier, attempts to shore up phosphorus levels in livestock ran into trouble because many phosphorus-containing supplements either tasted foul, came with safety questions, or simply passed through the gut without enough absorption. After years of tweaking, chemical engineers landed on butafosfan—a compound with 4-[(bis(2-hydroxyethyl)amino)butyl]phosphonic acid—blending organic phosphorus with a structure that animals can use. Over time, butafosfan moved from specialty status toward broader use in regions focused on dairy, swine, and performance horses. Commercialization grew in step with animal husbandry modernization and economic pressures to fend off metabolic disorders like ketosis while minimizing side effects.
Butafosfan usually arrives as a clear, colorless to pale-yellow aqueous solution, designed for injection. Products combine butafosfan with vitamin B12 more often than not—a duo that reflects a common belief among veterinarians that stressed or weak animals tend to lack both phosphorus reserves and cobalamin. Bottles ship as concentrate for veterinary use, most often sealed in amber glass to keep light at bay and slow down oxidation. Formulations avoid added preservatives, because clinical experience showed even mild additives sometimes produce adverse reactions in cattle or horses. Out in the field, users rely on strict protocols for handling, injecting, and discarding solutions, reflecting hard-earned lessons in sterility and safety.
Butafosfan balances non-volatility with high water solubility, thanks to its specific arrangement of functional groups. The chemical formula, C7H18NO5P, registers a molecular weight of about 243.2 g/mol. Users never mistake its moderately acidic character or its faint, distinctive smell. Technicians find its high polarity an asset during mixing with saline or glucose solutions in clinical settings. The compound avoids the issues of precipitation or oiliness that plague inorganic phosphorus salts. Despite its robust profile, butafosfan won’t tolerate temperatures above 25°C for long, which taught shippers hard lessons in cold-chain logistics, especially across hot climates.
Butafosfan injections must meet tough veterinary standards set by bodies like the European Pharmacopoeia or the United States Pharmacopeia. Typical products hold up to 10% butafosfan, often paired with 0.005% cyanocobalamin if vitamin B12 joins the mix. Labels list strength, batch number, manufacturing date, and expiration, along with storage instructions to avoid direct sunlight, freezing, or prolonged high temperatures. Regulatory law demands clear warning statements about not using butafosfan in uncertified food-producing animals during withdrawal periods. Syringes and multidose vials come with color-coded caps and traceable barcodes to ensure counterfeiters don’t sneak look-alike products into the supply chain.
Chemists make butafosfan by condensing N,N-bis(2-hydroxyethyl)butylamine with phosphorous acid, using acid catalysts and careful temperature controls. This flow avoids side-products that reduce purity or produce toxic residues. After heating and neutralization, purification happens in stages—filtration, vacuum evaporation, and fine ion-exchange resins. Manufacturers split the process into tightly controlled lots, since batch variation poses clinical risk. I’ve watched lab teams triple-check for heavy metal traces or residual solvents. Any deviation can mean a loss of the entire batch, so quality control gets the sharpest focus. Finished compound dissolves quickly in sterile water, and undergoes microfiltration before bottling under sterile conditions.
Butafosfan’s phosphonic acid group and dihydroxyethyl substituents give it reaction flexibility without volatility. Under acid or base catalysis, the compound can produce various phosphorylated analogs, but these don’t get into mainstream veterinary use due to potential toxicity or unstable profiles. It resists oxidation at room temperature, though enough exposure to heat or strong acids eventually break bonds, releasing phosphite and organic amines. Some labs experimented with adding antioxidants during formulation, hoping to lengthen shelf life, but real-world use didn’t show much benefit, given the compound’s natural stability.
Butafosfan sometimes goes by alternate names, including “Butaphosphan,” or, less often, “Butyldiethanolaminophosphonic acid.” Commercial injections hit the market under names like Catosal, PhosPHAN, and Herafosfan, depending on region or manufacturer. Trade names often reflect brand registration or local regulatory quirks. Regardless of label, professional buyers quickly scan for the word ‘butafosfan’ or the CAS number 17316-67-5 to tell the real deal from variants or knock-offs.
On every farm or veterinary practice I’ve seen, handling butafosfan comes with a strong set of protocols born from both regulation and on-the-ground learning. Staff wear gloves, check expiration dates, and keep vials in temperature-controlled storage. Labeling makes sure no dose lands in an animal destined for immediate slaughter, to head off any risk of residue in meat or milk. Emergency protocols address accidental self-injection, which, while rare, requires prompt flushing and medical follow-up. Disposal of used needles runs through locked sharps containers, again reflecting real cases of accidental stick injuries among hurried barn workers. Every year, audits check compliance with handling and documentation, because regulators stay alert to residue, mislabeling, or off-label use as real public health threats.
Butafosfan found its niche in livestock and equine medicine, mostly to treat or prevent metabolic disorders tied to phosphorus deficiency. Dairy herds get the most attention, as drops in blood phosphorus during early lactation bring metabolic crashes including ketosis, weakness, and lost milk yield. Swine herds see benefit too, especially among sows during late gestation or acute stress. Veterinary teams rely on butafosfan for horses bouncing back from hard training, viral infections, or travel-induced exhaustion. The compound sees less use in small animals like dogs and cats, though some clinics have reported benefit in cases of prolonged anorexia or generalized weakness. Demand rises during calving and farrowing seasons, when herd stress peaks and even small nutrient deficits turn into major economic setback. Anecdotal evidence from practitioners suggests it restores vigor surprisingly fast, leading to wider adoption even in regions slow to accept new drugs.
Research into butafosfan’s effects picked up in the last twenty years as animal agriculture pressured suppliers for safer, more reliable supplements. Controlled studies in dairy cattle show faster recovery from negative energy balance and improved appetite with butafosfan plus vitamin B12, compared to plain phosphorus or vitamin injection alone. There’s growing evidence that butafosfan modulates stress response in both swine and cattle, likely by influencing hepatic glucose output and insulin sensitivity. Academics present their results at veterinary conferences, spurring still more interest from the field. Molecular biologists chase down the compound’s precise pathway, with a working hypothesis pointing to upregulated gluconeogenesis and better mitochondrial efficiency. Despite growing literature, gaps remain—long-term impacts, carryover into edible tissues, and possible synergy with other metabolic drugs all need more work before regulators and producers sign off on new uses.
Toxicologists dug into butafosfan’s safety after reports of short-term restlessness or muscle tremor post-injection in sensitive animals. Standard toxicology studies in rats, dogs, and cattle show a large safety window when guidelines are followed, with a high threshold for acute toxicity. Problems appear mostly with gross overdose, contaminated batches, or improper storage. In practice, reported incidents track back to user error—a pattern seen across many injectable supplements. Carcinogenicity and reproductive toxicity look low, though global authorities like the EMA and FDA call for ongoing surveillance. Withdrawal periods for meat and milk address public health concerns by ensuring residue clearance. Questions about possible off-target immune suppression or interaction with common vaccines have not panned out under current data, but vigilance continues, especially as new molecular techniques offer deeper probing.
Butafosfan stands at a crossroads alongside shifts in animal agriculture and consumer expectations for food safety. Market demand for high-efficiency, fast-acting supplements won’t ease up, and butafosfan’s energy-metabolic benefits fit that bill more than many arcane mineral mixtures or unproven herbal boosters. Ongoing trials chase new formulations—slow-release implants or blends with emerging metabolic drugs—to stretch its impact through sensitive periods in herd productivity. Sustainability advocates want to see proof that targeted use of butafosfan aids animal welfare and reduces fallback antibiotic use. Future labeling may include QR codes, real-time tracking, or blockchain links to lock down supply-chain transparency. Next-generation toxicity studies adopt long-view, multi-generational models, seeking out any hint of subtle metabolic disturbances or environmental residue impact. The bigger hope hangs on rigorous research, honest field experience, and open dialogue between those who create, prescribe, and use these products—with butafosfan showing by its long track record that innovation stays grounded best through both evidence and practical know-how.
Butafosfan probably isn’t a word most people hear thrown around at coffee shops, but in the world of animal agriculture, it makes a difference for both farmers and veterinarians. This organophosphorus compound stands out not because of some marketing gimmick, but because of hard, observable results when animals face stress. Livestock don’t care about theory—they show it in their weight gains, their energy, and how quickly they bounce back from tough times.
Butafosfan works by making phosphorus easier for an animal to use. In my experience growing up around livestock, phosphorus always played a bigger part than most people realized. If animals start dragging their feet or eating less, many times, you’ll find phosphorus levels aren’t where they should be. Phosphorus keeps the energy cycle humming and supports everything from appetite to milk production. Cattle, pigs, goats, and horses all need it—especially if they’re under stress from transport, calving, sickness, or a heavy production schedule.
Researchers back this up, too. Veterinary studies repeat the same pattern: stressed animals given butafosfan show better appetite and recover faster. One published study showed dairy cows treated with butafosfan plus vitamin B12 after calving increased their feed intake and staved off metabolic problems. This isn’t just good for animal well-being—it helps reduce economic losses on the farm.
Most often, butafosfan gets used alongside vitamin B12. It’s usually injected—not fed—so it acts fast. Vets pull it off the shelf for dairy cows right after tough calvings or for young pigs moving through weaning, a period that can make or break a batch’s performance. If you’ve seen a sluggish calf start drinking and moving hours after its shot, you understand why people keep it in stock.
Butafosfan isn’t some magic bullet, though. Nutrition matters, so feed quality and management have to stay on point. Think of it like jumper cables for a run-down battery: it gets things started, but the battery still needs to hold a charge. Skimping on daily nutrition because you can use a supplement like butafosfan leads to long-term issues down the road.
The welfare side matters, too. In today’s world, consumers want assurance that farms put animal well-being first. That’s not just talk—studies show improving stress recovery directly links to healthier animals, which in turn helps keep food safe for humans. Using tools that support this, rather than relying on constant medications, fits with a smarter, more responsible approach to farming.
If the goal is healthier animals and better farm productivity, butafosfan makes a case for its place in the vet’s toolkit. Still, there’s no substitute for training, observation, and day-to-day care. What butafosfan offers is a proven bump when animals hit a rough patch. Looking ahead, continued research will help clarify exactly how and when it works best—not just in lab settings, but right out in the barn, where it counts.
Farmers and veterinarians often face tough decisions when livestock starts showing signs of metabolic stress or lagging performance. Every season brings its own pressures, from calving and heavy work to dietary gaps, and animals can show signs of exhaustion or weakness—sometimes overnight. Butafosfan isn't just another supplement on the market—its track record comes from helping animals bounce back by supporting their organs’ natural phosphorus processes. Phosphorus carries energy and supports stamina, so it’s not surprising so many producers and animal health technicians turn to Butafosfan, especially for cattle, horses, pigs, sheep, and even pets when they look worn down.
In daily practice, Butafosfan is given by injection, almost always by a veterinarian or under veterinary supervision. The bottle comes as a sterile liquid for injection and usually shares the shelf with B12, because they combine well for treating fatigue or poor appetite. Unlike oral supplements, an injection makes sure the animal gets the right dose right away, with no guesswork over gut absorption.
The vet draws up the prescribed amount—how much depends on body weight and the animal’s condition—and injects it under the skin (subcutaneously) or directly into the muscle (intramuscularly). This practical method helps busy farms treat several animals for a fast turnaround during times of strain, like peak lactation or after giving birth.
Accepting an injection works because there’s little room for hesitation; the job must get done before stress or sickness deepens. No animal enjoys a shot, but the relief often comes quick when Butafosfan works alongside supportive treatments, including proper feed or electrolytes. Farmers I know trust their local vet with dosing, yet they stay involved by keeping records, watching for allergic reactions (which are rare), and looking for improvement within days.
It’s easy to forget the challenges that appear with oral dosing—especially in herds that pass water quickly or picky eaters who dodge supplements in their feed. But with injection, the owner doesn't have to wonder if the animal spat it out or let the powder sink to the bottom of a trough.
Storage and shelf life matter on farms with limited resources. Liquid Butafosfan needs to stay in a cool, dark place, and once a vial is opened, it should be used up in a reasonable time to prevent contamination. Here, good training and organization save wasted medicine.
Consumers expect farmers to minimize unnecessary drugs, and that’s where Butafosfan stands out. Timely support can mean fewer chronic problems and lower antibiotic use down the road. There are guidelines for withdrawal periods in food animals, so vets coordinate with producers to avoid leaving residues in meat or milk. This kind of planning reassures the public and protects farmers from penalties.
The science behind Butafosfan supports what experienced animal caretakers already sense in the field: energy and performance rely on more than just calories—they depend on unlocking the right nutrients at the right time. Ongoing studies can help refine how it’s used across species, but farmers and vets have shaped best practices by watching results in the barn, not just in the lab.
Clear communication with animal health professionals creates a feedback loop that improves protocols and supports animal well-being, which matters to everyone from ranchers to consumers.
Butafosfan ends up on the radar of vets and farmers mainly because it promises a boost in metabolism and relief from stress. This organophosphorus compound, paired with vitamin B12, lands in injection form for cattle, pigs, horses, and dogs. The intent: help animals bounce back from stress, fight off fatigue, or get through periods of rapid growth. Most people who use it expect animals to perk up and eat better. Its usage stretches across countries and animal sectors. Yet, with benefits, questions about side effects always linger.
Most published studies and field reports don’t list a laundry list of severe problems. In routine veterinary settings, butafosfan is often given a clean bill of health. Still, any chemical introduced into a living system has a chance to stir up trouble. Experienced vets sometimes report mild reactions at the injection site—a little swelling, some pain, or redness. These spot reactions tend to clear up on their own, and rarely need treatment beyond a little monitoring.
Systemic reactions remain uncommon but not impossible. A veterinarian’s experience can confirm that, especially if animals already struggle with another illness, the risk rises. Weak animals or those battling liver and kidney issues could have a tougher time getting rid of excess phosphorus. Animals who take a bad turn after treatment may display symptoms like restlessness, muscle tremors, or abnormal heart rhythms. These signals prompt vets to reconsider the benefit of more injections.
Formal studies back up real-world experience. The European Medicines Agency reviewed butafosfan and didn’t link it with chronic health problems or reproductive damage. Still, agencies tell farmers and pet owners to avoid injecting more than recommended. Overdoses, as reported in some veterinary cases, might put organs under pressure, especially in newborn or very old animals.
Recent journal reviews point out that butafosfan breaks down fast and leaves the animal’s system in a short span. Because of this, concerns about drug residues in milk or meat stay fairly low. On farms where withdrawal times count, this fact gets attention. The compound seems gentle in animals that are healthy and dosed correctly, but there’s no reason to overlook rare complications.
During my years on farms and working with mixed veterinary practices, the standard rule for butafosfan lined up with other medications: Don’t skip the basics of animal care. Stress or low appetite often point to something deeper—poor nutrition, infections, or tough weather. In my experience, those who rely only on drug intervention usually miss bigger issues. Butafosfan won’t replace a balanced ration or proper shelter.
Animals vary. A beef herd in northern climates might not show the same response as dairy cows on a high-carb ration, even if both receive the same dose. One dog’s metabolism won’t match another’s, regardless of pedigree. Tailoring treatment to each animal, considering their overall health, and sticking close to recommended protocols goes a long way.
Solid recordkeeping—dates, doses, observed side effects—helps track patterns. If unexpected swelling, fever, or behavior changes surface after an injection, stopping treatment and calling the vet counts more than pushing through. Training staff to watch for odd symptoms after drug use often pays off, especially with new or sensitive animals.
Extra caution makes sense for pregnant or lactating animals, even if studies say risks are small. Vets find value in starting with the lowest effective dose, rather than maxing out from the start. Open communication with suppliers and tracking updated literature limits surprises. Butafosfan has won trust in many circles, but respect for its power and possible downsides always matters.
Butafosfan draws attention in livestock management, especially among cattle, pigs, and sheep farmers facing sudden drops in energy or appetite in their herds. It is a phosphorus-based compound, and veterinarians often turn to it for animals under stress—think calving cows, dairy cattle after calving, or sheep after heavy parasite burdens. Over the years, I’ve come across enough cases where a boost with Butafosfan helped a sluggish animal back onto its feet. It isn’t a silver bullet, but it serves as a crutch during a bad stretch.
Dosing isn’t about one-size-fits-all. Labels from respected manufacturers stick with a range: Cattle usually receive 5 to 10 milliliters per 100 kilograms of body weight. For calves or smaller stock, the common suggestion lands between 2.5 to 5 milliliters per 50 kilograms. Swine typically get the same per-weight recommendations. Sheep and goats—2.5 to 5 milliliters per 50 kilograms. Dosing happens once daily, sometimes for three to five days, with a subcutaneous or intramuscular injection. This isn’t a take-it-and-leave-it situation. Monitoring is crucial.
Underdosing leaves the animal limping along, still struggling. Giving too much can bring headaches, especially because sensitive animals can react to excess phosphorus. I’ve seen herds pick up after a careful Butafosfan protocol, mostly when supported by vet oversight and solid feeding practices. Blindly pushing the upper limits means risking toxic reactions. According to the European Medicines Agency, toxicity stays unlikely at label dosages but grows if farmers guess without weighing, or skip the vet’s advice. Hardcore feed science keeps reminding us: phosphorus matters, but balance works better than brute force.
Veterinarians stress checking why an animal lags in the first place. Just shooting Butafosfan without chasing the cause makes little sense. From personal experience, stressed cows after calving may bounce back when Butafosfan joins good feed and supportive care. On the flip side, a skinny sheep riddled with worms needs parasite management above all, with vitamins and Butafosfan as backup. It all comes down to context—age, weight, current feed quality, and health issues play into choosing the dosage and frequency.
The World Health Organization and several veterinary compendiums confirm large trials where the suggested label dosages showed no widespread side effects. Reports from European and US livestock clinics point out rare problems tied to overzealous use or ignoring other mineral imbalances. Farmers have learned that following professional guidelines not only helps animals recover but protects the operation from regulatory headaches. Oversight from trained vets and regular record-keeping get highlighted in animal health training courses for good reason.
Butafosfan gives herds a boost, but it thrives as part of a broader care plan. No shortage of science says working closely with a vet beats guessing by eye. Only with this approach does the recommended dosage carry real weight—because it’s tailored, checked, and backed by hands-on monitoring. Livestock owners benefit when they link recommended dosing with care, solid nutrition, and early vet visits for slow-recovering stock.
Folks who work with livestock know that pregnancy and lactation push animals to their limits. Even with the best care, sometimes cows and sows just don’t bounce back as quickly as you’d hope after calving or farrowing. That’s where folks turn to supportive treatments, and butafosfan comes up in conversation more often than you might think. On real farms, tough decisions get made each day—do we give this phosphorus-boosting solution, or play it safe and avoid?
Butafosfan, usually combined with vitamin B12, offers phosphorus in a form animals can use fast. Phosphorus plays a big role in energy metabolism. After helping with calving or handling post-parturient paresis (milk fever), butafosfan has found an unofficial spot in the vet’s kit for animals under metabolic stress. A 2022 review in Veterinary Medicine and Science pulled together published research and found no obvious red flags for birth defects, abortions, or milk contamination when used at recommended doses in cows, pigs, or goats. Most studies point to improvement in energy levels, better mothering, and reduced downtime after giving birth.
But here’s the catch: only a handful of those studies looked at truly pregnant or lactating animals. Even fewer followed the newborns or measured drug levels in milk long-term. Regulatory bodies, especially in the US and Europe, recommend caution. They stress sticking to label indications—most products don’t list pregnancy or lactation as approved uses, often due to missing data rather than clear evidence of harm.
Ask any vet in the field, and most will admit butafosfan gets used when nothing else seems to shift a sluggish cow post-calving. You see it in subclinical ketosis cases when feeding doesn’t bring animals around. Older textbooks mention it in ewes at lambing time, but always with a note of “only if nothing else works” and under close watch. What these cases share is a need for careful judgement. Nobody wants to play roulette with a stressed mother or her calf, but skipping a possible lifesaver can cost lives and income.
I’ve watched experienced farm vets run a careful risk-benefit check: Was the cow healthy before pregnancy? Has she had calcium or metabolic issues before? What’s her body score—thin or thriving? No decision here comes lightly. Veterinarians act with caution, often phoning a trusted pharmacologist or scouring the literature for anything hinting at risk. They document everything, keeping the client and regulators on the same page.
Until manufacturers run dedicated safety trials in pregnant and lactating animals, this will remain a gray area. Farmers, vets, and pharmacists work together, pooling knowledge from academic studies, field experience, and animal health reports. It pays to keep updated on new findings—recent years brought a flurry of research from dairy-heavy regions. If you’re a farmer, talk openly with your vet; never skip that conversation in favor of online chatter or quick fixes.
Everyone deserves clear, honest answers about what’s safe for a mother animal and her young. More targeted studies would help, especially tracking outcomes in both dams and offspring. Regulators could push for clearer label updates as evidence builds. For now, real-world caution and teamwork remain the best safeguards. Animal welfare and food safety both depend on respect for the unknown.
| Names | |
| Preferred IUPAC name | N,N-bis(phosphonochloridoylmethyl)butan-1-amine |
| Other names |
Butaphosphan Butafosfanum |
| Pronunciation | /ˌbjuː.təˈfɒz.fæn/ |
| Preferred IUPAC name | [Butan-1-yl(dihydroxyphosphoryl)amino]formic acid |
| Other names |
Butafosphan Butafosfanum Butafosphan sodium Butaphosphan Buthafosfan |
| Pronunciation | /bjuːˈtæf.ɒz.fæn/ |
| Identifiers | |
| CAS Number | [17316-67-5] |
| Beilstein Reference | 3792740 |
| ChEBI | CHEBI:31207 |
| ChEMBL | CHEMBL2104747 |
| ChemSpider | 83155 |
| DrugBank | DB11455 |
| ECHA InfoCard | ECHA InfoCard: 100.056.496 |
| EC Number | 246-714-6 |
| Gmelin Reference | 94317 |
| KEGG | C18236 |
| MeSH | D017944 |
| PubChem CID | 3034411 |
| RTECS number | WK8765000 |
| UNII | NCP3N4804I |
| UN number | UN2902 |
| CAS Number | [17316-67-5] |
| Beilstein Reference | 1621272 |
| ChEBI | CHEBI:31211 |
| ChEMBL | CHEMBL2106028 |
| ChemSpider | 33711 |
| DrugBank | DB11479 |
| ECHA InfoCard | ECHA InfoCard: 100.060.481 |
| EC Number | 246-933-1 |
| Gmelin Reference | 104090 |
| KEGG | C18517 |
| MeSH | D017105 |
| PubChem CID | 6436029 |
| RTECS number | WS4400000 |
| UNII | 655Y6G9Y5X |
| UN number | UN2902 |
| Properties | |
| Chemical formula | C7H18O2PS |
| Molar mass | 462.420 g/mol |
| Appearance | Colorless or slightly yellow transparent liquid |
| Odor | Odorless |
| Density | 1.18 g/cm³ |
| Solubility in water | soluble |
| log P | -3.4 |
| Vapor pressure | 5.43E-09 mmHg at 25°C |
| Acidity (pKa) | 10.52 |
| Basicity (pKb) | 12.26 |
| Refractive index (nD) | 1.470 |
| Viscosity | Viscosity: 5.0–7.0 mPa·s |
| Dipole moment | 4.04 D |
| Chemical formula | C7H18O2PS |
| Molar mass | 306.167 g/mol |
| Appearance | Colorless or slightly yellow transparent liquid |
| Odor | Odorless |
| Density | 1.19 g/cm³ |
| Solubility in water | Soluble |
| log P | -2.0 |
| Vapor pressure | < 0.01 Pa (20 °C) |
| Acidity (pKa) | 5.45 |
| Basicity (pKb) | 12.46 |
| Refractive index (nD) | 1.525 |
| Viscosity | Viscosity: 12-16 mPa·s |
| Dipole moment | 6.20 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 216.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4396 kJ/mol |
| Std molar entropy (S⦵298) | 416.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4151 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | QA16QA01 |
| ATC code | QA12CX91 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin and serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, Warning, H302, P264, P270, P301+P312, P330 |
| Pictograms | GHS05", "GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. |
| Precautionary statements | P264, P270, P280, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 100 °C |
| Lethal dose or concentration | LD50 (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Butafosfan: "2,000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | 0.01 mg/kg |
| REL (Recommended) | 120 mg/kg |
| IDLH (Immediate danger) | Not established |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 100°C |
| Lethal dose or concentration | LD50 (oral, rat): 1000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Butafosfan: "2,600 mg/kg (rat, oral) |
| NIOSH | Not listed |
| PEL (Permissible) | PEL for Butafosfan: Not established |
| REL (Recommended) | 10 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Fosfomycin Phosphomycin Organophosphates |
| Related compounds |
Phosphorus acid Phosphorous acid Phosphonic acid Nicotinamide Cyanocobalamin |